Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease

Abstract

Declaration of financial/other relationshipsCIC has received research funding and honoraria from Janssen Scientific Affairs, LLC; Bayer AG; and Alexion Pharmaceuticals. AAK and BB are Janssen Pharmaceuticals employees. WLB has not conflicts to declare. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.